Loading...
Please wait, while we are loading the content...
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial.
| Content Provider | Europe PMC |
|---|---|
| Author | Slagter, Astrid E. Vollebergh, Marieke A. Caspers, Irene A. van Sandick, Johanna W. Sikorska, Karolina Lind, Pehr Nordsmark, Marianne Putter, Hein Braak, Jeffrey P. B. M. Meershoek-Klein Kranenbarg, Elma van de Velde, Cornelis J. H. Jansen, Edwin P. M. Cats, Annemieke van Laarhoven, Hanneke W. M. van Grieken, Nicole C. T. Verheij, Marcel |
| Abstract | AimTo evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer.MethodsWe performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data.ResultsIn multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11–1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42–2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters.ConclusionCEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position.Trial registrationClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10120-021-01258-6. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8882113&blobtype=pdf |
| ISSN | 14363291 |
| Journal | Gastric Cancer |
| Volume Number | 25 |
| DOI | 10.1007/s10120-021-01258-6 |
| PubMed Central reference number | PMC8882113 |
| Issue Number | 2 |
| PubMed reference number | 34714423 |
| e-ISSN | 14363305 |
| Language | English |
| Publisher | Springer Singapore |
| Publisher Date | 2021-10-29 |
| Publisher Place | Singapore |
| Access Restriction | Open |
| Rights License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2021 |
| Subject Keyword | Tumor markers CEA CA 19-9 ctDNA Resectable gastric cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Gastroenterology Oncology |
